Not many are feeling that pain more from the weak U.S. dollar than Novo Nordisk — the world’s No. 1 provider of insulin. Chief Financial Officer Jesper Brandgaard’s sighs bookend his response to just how bad currency is hurting his Danish company.
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/